258503-93-4

Basic information

• Product Name: 6-QUINOXALINECARBONYL CHLORIDE
• Synonyms: 6-QUINOXALINECARBONYL CHLORIDE;Quinoxaline-6-carbonyl chloride;6-Quinoxalinecarbonyl chloride (9CI);6-(Chlorocarbonyl)quinoxaline;Quinoxaline-6-carboxylic acid chloride;6-(Chlorocarbonyl)quinoxaline, 6-(Chlorocarbonyl)-1,4-benzodiazine;6-QUINOXALINECARBONYL CHLORIDE-3
• CAS NO: 258503-93-4
• Molecular Formula: C₉H₅ClN₂O
• Molecular Weight: 192.6
• Product Categories: ACIDHALIDE
• Mol File: 258503-93-4.mol
• Article Data: 12

Chemical Properties

• Melting Point: 119 °C
• Boiling Point: 324.4 °C at 760 mmHg
• Flash Point: 150 °C
• Appearance: /
• Density: 1.411g/cm³
• Vapor Pressure: 0.000246mmHg at 25°C
• Refractive Index: 1.662
• CAS DataBase Reference: 6-QUINOXALINECARBONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-QUINOXALINECARBONYL CHLORIDE(258503-93-4)
• EPA Substance Registry System: 6-QUINOXALINECARBONYL CHLORIDE(258503-93-4)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-36
• Safety Statements: 26-36/37/39
• RIDADR: 3261
• Hazardous Substances Data: 258503-93-4(Hazardous Substances Data)

Usage

General Description

6-Quinoxalinecarbonyl chloride is a chemical compound with the formula C8H5ClN2O. It is a colorless, slightly yellowish liquid that is used in the synthesis of other organic compounds. It is a versatile reagent in organic chemistry, as it can react with a variety of nucleophiles to form a wide range of products. It is commonly used in the pharmaceutical and agricultural industries for the production of drugs and crop protection chemicals. Additionally, it is also used as an intermediate in the synthesis of dyes and pigments. However, 6-Quinoxalinecarbonyl chloride is a highly reactive and toxic compound and should be handled with caution.

InChI:InChI=1/C9H5ClN2O/c10-9(13)6-1-2-7-8(5-6)12-4-3-11-7/h1-5H

Upstream product

• 6925-00-4 quinoxaline-6-carboxylic acid 
• 619-05-6 3,4-diaminobenzoic acid 
• 107-83-5 2-Methylpentane 
• 23088-23-5 methyl quinoxaline-6-carboxylate 

Downstream Products

• 701979-19-3 4-[1-(6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-1H-[1,2,4]triazol-3-yl]-benzonitrile 
• 356560-90-2 2-(6-methylpyridin-2-yl)-1-(quinoxalin-6-yl)ethanone 
• 364050-21-5 1-(6-methylpyridin-2-yl)-2-(quinoxalin-6-yl)ethane-1,2-dione 
• 442517-38-6 2-(dimethoxymethyl)-5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazole 
• 130345-50-5 quinoxaline-6-carbaldehyde 
• 875558-38-6 N-methoxy-N-methylquinoxaline-6-carboxamide 
• 937279-41-9 quinoxaline-6-carboxylic acid N,N'-dimethylhydrazide 
• 1240019-51-5 ND₀₀₂₂ 

Relevant articles and documents

Triketone compound containing quinoxaline structure, and preparation method and application thereof

The invention belongs to the technical field of medicine synthesis, and particularly relates to a triketone compound containing a quinoxaline structure, and a preparation method and an application thereof. The quinoxaline-containing triketone compound has a structure represented by general formula (I). The preparation method is mainly characterized in that a compound with a structure represented by formula (II) is contacted in the presence of an alkali and a solvent, and R1, R2, R3 and R4 in the formulas are respectively defined in the description. The quinoxaline-containing triketone compoundhas high herbicidal activity, and especially has an excellent effect of preventing and controlling broadleaf weeds and/or gramineous weeds, and the prevention and control effect is even better than that of some commercial herbicides sold in the market.

Substituted Pyrazalones

The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such a

Novel Quinoxaline Derivatives and Their Medical Use

This invention relates to novel quinoxaline derivatives having medical utility, to use of the quinoxaline derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinoxaline derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to positive modulation of AMPA receptor mediated synaptic responses.